Ouyang Anli, Yang Shang-Tian
Eli Lilly and Company, Bioprocess Research and Development, Lilly Corporate Center, DC 3945, Indianapolis, IN 46285, USA.
Expert Opin Biol Ther. 2008 Jul;8(7):895-909. doi: 10.1517/14712598.8.7.895.
Embryonic stem cells (ESCs) have unlimited proliferation potential and can differentiate into all cell and tissue types, and thus are ideal sources for cell therapy and drug screening. Current supplies of ESCs are limited by the available cell sources and inefficient culture methods that grow ESCs on surfaces coated with expensive extracellular matrix (ECM) proteins and in media containing expensive growth factors.
To meet the demand for ESCs, it is necessary to develop an economical process for their mass production.
We review the latest development in in vitro ESC culture and introduce a two-stage perfusion bioreactor system that uses 3-D fibrous matrices and conditioned media for production of ESCs.
RESULTS/CONCLUSION: The two-stage process can produce billions of ESCs in a small bioreactor without using ECM proteins and growth factors, and is promising for further scale-up for clinical applications.
胚胎干细胞（ESCs）具有无限增殖潜力，可分化为所有细胞和组织类型，因此是细胞治疗和药物筛选的理想来源。目前胚胎干细胞的供应受到可用细胞来源以及低效培养方法的限制，这些培养方法是在涂有昂贵细胞外基质（ECM）蛋白的表面和含有昂贵生长因子的培养基中培养胚胎干细胞。
为满足对胚胎干细胞的需求，有必要开发一种经济的大规模生产方法。
我们综述了体外胚胎干细胞培养的最新进展，并介绍了一种两阶段灌注生物反应器系统，该系统使用三维纤维基质和条件培养基来生产胚胎干细胞。
结果/结论：该两阶段方法可在小型生物反应器中生产数十亿的胚胎干细胞，无需使用细胞外基质蛋白和生长因子，并且有望进一步扩大规模用于临床应用。
